Can-Fite
is an Israeli biopharmaceutical company with fully integrated pharmaceutical
discovery and clinical development capabilities. The company has
diverse pipeline of proprietary compounds that address inflammatory,
ophthalmic, cancer and viral diseases.
The company platform
technology utilizes the Gi protein associated A3
adenosine receptor (A3AR) as a therapeutic
target. A3AR is highly expressed in inflammatory
and cancer cells where low expression is found in normal cells.
The company pipeline
drugs are synthetic, highly specific agonists and allosteric modulators
targeting the A3 adenosine receptor. All drugs are orally bioavailable
with an excellent safety profile. The company’s lead drugs
are CF101 and CF102,
both are small-molecule oral drugs that are safe and very well tolerated.
CF101 has shown activity
in Psoriasis, Dry Eye Syndrome and Rheumatoid Arthritis in Phase
II studies. CF102, is currently being tested in
two Phase I/II studies: one in hepatocellular carcinoma and the
other in patients with hepatitis C viral infection. |
